Business · 17/11/20261 min read
Onward Therapeutics Closes NT$900 Million (approximately US$28 Million) Series B Financing to Advance Clinical-Stage Oncology Pipeline
Summary
First capital increase since relocating global headquarters to Taiwan; Company targets Emerging Stock Board registration by the end of 2027 TAIPEI and EPALINGES, Switzerland and PARIS, Nov. 17, 2026 — Onward Therapeutics, Inc. ("Onward Therapeutics" or the "Company") today...